Until now, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved two inhibitors of SMO for the treatment of laBCC that has recurred following surgery or radiotherapy or for those who are not eligible for surgery or radiotherapy, as well as metastatic BCC, where vismodegib was the first selective Hh inhibitor approved in 2012. Here, SMO is linked to skin basal cell carcinoma.